Haemophilus influenzae b is the leading cause of death and morbidity in children, and its six entities are meningitis, bacterial pneumonia, epiglottitis, septicaemia, cellulitis and bone and joint infections.HIB disease is the cause of about 90 percent of child deaths each year.HIB vaccines are effective and safe for infants because they contain polyribonitol phosphate that binds to proteins in response to meningitis and pneumonia in children.
This report contains market size and forecasts of Haemophilus Influenzae Type B Vaccine in global, including the following market information:
Global Haemophilus Influenzae Type B Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Haemophilus Influenzae Type B Vaccine Market Sales, 2017-2022, 2023-2028, (M Doses)
Global top five Haemophilus Influenzae Type B Vaccine companies in 2021 (%)
The global Haemophilus Influenzae Type B Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Liquid Monovalent HIB Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Haemophilus Influenzae Type B Vaccine include Novartis, Merck, Sanofi, GlaxoSmithKline, Takeda Pharmaceuticals Company, Walvax Biotechnology, Lanzhou Institute of Biologica and Immunize BC, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Haemophilus Influenzae Type B Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Haemophilus Influenzae Type B Vaccine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Doses)
Global Haemophilus Influenzae Type B Vaccine Market Segment Percentages, by Type, 2021 (%)
Liquid Monovalent HIB
Liquid Combination HIB
Lyophilized Monovalent HIB
Lyophilized Combination HIB
Global Haemophilus Influenzae Type B Vaccine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Doses)
Global Haemophilus Influenzae Type B Vaccine Market Segment Percentages, by Application, 2021 (%)
Hospital
Research Institutions
Pharmaceutical and Biotechnology Companies
Academic Institutions
Other
Global Haemophilus Influenzae Type B Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Doses)
Global Haemophilus Influenzae Type B Vaccine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Haemophilus Influenzae Type B Vaccine revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Haemophilus Influenzae Type B Vaccine revenues share in global market, 2021 (%)
Key companies Haemophilus Influenzae Type B Vaccine sales in global market, 2017-2022 (Estimated), (M Doses)
Key companies Haemophilus Influenzae Type B Vaccine sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Merck
Sanofi
GlaxoSmithKline
Takeda Pharmaceuticals Company
Walvax Biotechnology
Lanzhou Institute of Biologica
Immunize BC